Thermo Fisher Scientific has recently acquired Belgium based, Henogen S.A., Novasep's viral vector manufacturing business for approximately €725 million in cash.
The viral vector manufacturing company of Novasep provides biotechnology companies and significant biopharma clients with contract manufacturing services for vaccines and therapies.
“Thermo Fisher Scientific acquires Novasep's viral vector manufacturing business for €725 million.“
Executive Vice President, Thermo Fisher, Michel Lagarde, stated: "Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally. The addition of their manufacturing capabilities in Europe complements our 4 development and manufacturing sites in North America. In addition, they bring an incredibly talented team with more than 2 decades of experience across a broad range of viral vectors. The combination will benefit our global customers seeking support and capacity in the region, as well as European customers bringing new medicines to patients inside and outside of Europe."
President and Chief Executive Officer, Novasep, Michel Spagnol, stated: "Thermo Fisher is an outstanding partner for our viral vector business and its future development. Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of Thermo Fisher. Our talented employees will bring deep expertise to an organization that shares our commitment to providing ground-breaking new medicines to patients."